Veru Q3 net income $6.3M on ENTADFI gain; pipeline updates for enobosarm, sabizabulin

VERU INC.

2023-Q3 EPS reported -$0.83 revenue$12,434,946

Net income $6.3M ($0.07/diluted share) vs net loss $22.2M ($0.28) in Q3 2022; revenue $3.3M down from $9.6M.
Cash burn reduced to $7.3M in Q3, down $16.1M from prior quarter; cash $16.2M at June 30, 2023.
Sold ENTADFI for $20M in April 2023; potential $80M in sales milestones. Gain of $17.5M recognized.
FDA agrees on Phase 3 ENABLAR-2 design; ORR endpoint in Stage 1 may support accelerated approval for enobosarm in metastatic breast cancer.
Plans to expand sabizabulin Phase 3 confirmatory study to all viral lung infections; FDA meeting scheduled for September 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

VERU INC. reported financial results for the quarter and nine months ended June 30, 2023.

Period: the quarter and nine months ended June 30, 2023
Result: reported results

Exact text from the filing

On August 10, 2023, Veru Inc. issued a press release (the “Press Release”) announcing results for the quarter and nine months ended June 30, 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

VERU INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-208059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.